146 related articles for article (PubMed ID: 8845574)
1. The role of biotherapies (interleukins, interferons and erythropoietin) in multiple myeloma.
Avvisati G; Petrucci MT; Mandelli F
Baillieres Clin Haematol; 1995 Dec; 8(4):815-29. PubMed ID: 8845574
[TBL] [Abstract][Full Text] [Related]
2. [The role of biotherapy in multiple myeloma].
Petrucci MT; Tafuri A; Mandelli F
Recenti Prog Med; 2000 Oct; 91(10):488-93. PubMed ID: 11072735
[TBL] [Abstract][Full Text] [Related]
3. [Cytokines in the treatment of blood diseases].
Robak T
Acta Haematol Pol; 1995; 26(2 Suppl 1):72-8. PubMed ID: 7544526
[TBL] [Abstract][Full Text] [Related]
4. Multiple myeloma. New treatment options.
Camba L; Durie BG
Drugs; 1992 Aug; 44(2):170-81. PubMed ID: 1382012
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumour activity of interferon-alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiation.
Matsui W; Huff CA; Vala M; Barber J; Smith BD; Jones RJ
Br J Haematol; 2003 Apr; 121(2):251-8. PubMed ID: 12694246
[TBL] [Abstract][Full Text] [Related]
6. Erythropoiesis and erythropoietin in multiple myeloma.
Beguin Y
Leuk Lymphoma; 1995 Aug; 18(5-6):413-21. PubMed ID: 8528047
[TBL] [Abstract][Full Text] [Related]
7. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
[TBL] [Abstract][Full Text] [Related]
8. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases.
Akdis M; Aab A; Altunbulakli C; Azkur K; Costa RA; Crameri R; Duan S; Eiwegger T; Eljaszewicz A; Ferstl R; Frei R; Garbani M; Globinska A; Hess L; Huitema C; Kubo T; Komlosi Z; Konieczna P; Kovacs N; Kucuksezer UC; Meyer N; Morita H; Olzhausen J; O'Mahony L; Pezer M; Prati M; Rebane A; Rhyner C; Rinaldi A; Sokolowska M; Stanic B; Sugita K; Treis A; van de Veen W; Wanke K; Wawrzyniak M; Wawrzyniak P; Wirz OF; Zakzuk JS; Akdis CA
J Allergy Clin Immunol; 2016 Oct; 138(4):984-1010. PubMed ID: 27577879
[TBL] [Abstract][Full Text] [Related]
9. Cytokines in breast cancer.
Nicolini A; Carpi A; Rossi G
Cytokine Growth Factor Rev; 2006 Oct; 17(5):325-37. PubMed ID: 16931107
[TBL] [Abstract][Full Text] [Related]
10. Modulation of interleukin-6/interleukin-6 receptor cytokine loop in the treatment of multiple myeloma.
Chen YH; Shiao RT; Labayog JM; Modi S; Lavelle D
Leuk Lymphoma; 1997 Sep; 27(1-2):11-23. PubMed ID: 9373192
[TBL] [Abstract][Full Text] [Related]
11. Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma.
Silvestris F; Romito A; Fanelli P; Vacca A; Dammacco F
Ann Hematol; 1995 Jun; 70(6):313-8. PubMed ID: 7632811
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of multiple myeloma.
Huang YW; Vitetta ES
Stem Cells; 1995 Mar; 13(2):123-34. PubMed ID: 7540468
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-6 sensitizes multiple myeloma cell lines for apoptosis induced by interferon-alpha.
Minami R; Muta K; Ilseung C; Abe Y; Nishimura J; Nawata H
Exp Hematol; 2000 Mar; 28(3):244-55. PubMed ID: 10720689
[TBL] [Abstract][Full Text] [Related]
14. Upregulated production of IL-6, but not IL-10, by interferon-alpha induces SOCS3 expression and attenuates STAT1 phosphorylation in myeloma cells.
Usui E; Nishii K; Katayama N; Lorenzo V F; Chen F; Monma F; Otsuki T; Shiku H
Hematol J; 2004; 5(6):505-12. PubMed ID: 15570293
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the therapeutic potential of cytokines, cytotoxic drugs and effector cell populations for the treatment of multiple myeloma using the 5T33 murine myeloma model.
Manning LS; Chamberlain NL; Leahy MF; Cordingley FT
Immunol Cell Biol; 1995 Aug; 73(4):326-32. PubMed ID: 7493769
[TBL] [Abstract][Full Text] [Related]
16. [Current therapy concepts in patients with multiple myeloma].
Heyll A; Schneider P; Bauser U; Kobbe G; Hünerlitürkoglu A; Aul C; Haas R
Dtsch Med Wochenschr; 2000 Oct; 125(40):1201-9. PubMed ID: 11075253
[No Abstract] [Full Text] [Related]
17. Treatment of multiple myeloma in elderly patients. New developments.
Ossenkoppele GJ
Drugs Aging; 1997 Aug; 11(2):152-64. PubMed ID: 9259178
[TBL] [Abstract][Full Text] [Related]
18. Differential human multiple myeloma cell line responsiveness to interferon-alpha. Analysis of transcription factor activation and interleukin 6 receptor expression.
Jelinek DF; Aagaard-Tillery KM; Arendt BK; Arora T; Tschumper RC; Westendorf JJ
J Clin Invest; 1997 Feb; 99(3):447-56. PubMed ID: 9022078
[TBL] [Abstract][Full Text] [Related]
19. Interferon-alpha in the treatment of multiple myeloma.
Khoo TL; Vangsted AJ; Joshua D; Gibson J
Curr Drug Targets; 2011 Mar; 12(3):437-46. PubMed ID: 21143148
[TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6.
Westendorf JJ; Ahmann GJ; Greipp PR; Witzig TE; Lust JA; Jelinek DF
Leukemia; 1996 May; 10(5):866-76. PubMed ID: 8656685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
